Literature DB >> 15558534

Bone resorption and "relative" immobilization hypercalcemia with prolonged continuous renal replacement therapy and citrate anticoagulation.

Pei-Li Wang1, Mary M Meyer, Susan L Orloff, Sharon Anderson.   

Abstract

Regional citrate anticoagulation is an alternative to heparin in patients with bleeding diatheses who require continuous renal replacement therapy (CRRT). The short-term metabolic consequences that occur with citrate anticoagulation are well described and usually manageable if established protocols are followed vigilantly. Because of its customary short-term nature, the long-term consequences of CRRT with citrate are less often considered and have not been reported. The authors present the case of a woman with multisystem organ failure and prolonged acute renal failure who required CRRT for 120 days. Throughout her hospital course, adequate regional anticoagulation was achieved by blocking the coagulation cascade via the chelation of calcium by citrate. Despite an appropriate drop in the postfilter ionized calcium level, by 8 weeks after the initiation of CRRT, the patient was able to normalize serum calcium levels without the customary calcium infusion. Bone resorption owing to prolonged immobilization leading to hypercalcemia is a known complication of critically ill patients. This problem is more pronounced in patients with high bone turnover rates owing to conditions such as secondary hyperparathyroidism. In this particular case, the chelation of calcium by citrate masked the ensuing immobilization hypercalcemia, resulting in marked bone loss and bilateral spontaneous femoral fractures in the context of normal calcium levels. In critically ill patients sustained with prolonged CRRT with citrate anticoagulation, bone resorption and "relative" immobilization hypercalcemia may manifest as normal serum calcium levels in the face of falling calcium infusion rate requirements.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558534     DOI: 10.1053/j.ajkd.2004.09.001

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  Treatment dose and the elimination rates of electrolytes, vitamins, and trace elements during continuous veno-venous hemodialysis (CVVHD).

Authors:  Thomas Datzmann; Karl Träger; Bernd Schröppel; Helmut Reinelt; Philipp von Freyberg
Journal:  Int Urol Nephrol       Date:  2018-04-02       Impact factor: 2.370

Review 2.  Regional citrate anticoagulation for RRTs in critically ill patients with AKI.

Authors:  Santo Morabito; Valentina Pistolesi; Luigi Tritapepe; Enrico Fiaccadori
Journal:  Clin J Am Soc Nephrol       Date:  2014-07-03       Impact factor: 8.237

3.  Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study.

Authors:  Yan Yu; Ming Bai; Zhang Wei; Lijuan Zhao; Yangping Li; Feng Ma; Shiren Sun
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

4.  An Observational Cohort Study of the 2-Month Use of Regional Citrate Anticoagulation in Maintenance Hemodialysis Patients with Cerebral Hemorrhage.

Authors:  Xiao Bi; Qi Zhang; Feng Zhuang; Wei Lu; Yingdeng Wang; Feng Ding
Journal:  Med Sci Monit       Date:  2021-04-16

5.  Citrate dose for continuous hemofiltration: effect on calcium and magnesium balance, parathormone and vitamin D status, a randomized controlled trial.

Authors:  Willem Boer; Tom Fivez; Margot Vander Laenen; Liesbeth Bruckers; Hans Jurgen Grön; Miet Schetz; Heleen Oudemans-van Straaten
Journal:  BMC Nephrol       Date:  2021-12-11       Impact factor: 2.388

6.  Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice.

Authors:  Heleen M Oudemans-van Straaten; Marlies Ostermann
Journal:  Crit Care       Date:  2012-12-07       Impact factor: 9.097

Review 7.  Clinical review: Patency of the circuit in continuous renal replacement therapy.

Authors:  Michael Joannidis; Heleen M Oudemans-van Straaten
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

8.  The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss - a case report.

Authors:  Matthias Klingele; Sarah Seiler; Aaron Poppleton; Philip Lepper; Danilo Fliser; Roland Seidel
Journal:  BMC Nephrol       Date:  2014-10-04       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.